awmsg logo



lopinavir/ritonavir (Kaletra®)


Reference No. 3557


Appraisal information

lopinavir/ritonavir (Kaletra®) 80 mg/20mg oral solution


Company: AbbVie Ltd
BNF category: Infections
NMG meeting date: 10/01/2018
AWMSG meeting date: 14/02/2018
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download